MAM
CBAY

Meeder Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Meeder Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,770
Closed -$77K – 2302
2020
Q3 		$77K Buy
+10,770
New +$57.6K 0.01% 856
2020
Q2 		– Sell
-3,519
Closed -$5K – 2571
2020
Q1 		$5K Buy
3,519
+2,150
+157% +$3.61K ﹤0.01% 1823
2019
Q4 		$3K Buy
1,369
+965
+239% +$3.63K ﹤0.01% 1960
2019
Q3 		$2K Sell
404
-1,586
-80% -$9.6K ﹤0.01% 2006
2019
Q2 		$14K Sell
1,990
-849
-30% -$9.61K ﹤0.01% 1359
2019
Q1 		$38K Buy
2,839
+2,142
+307% +$22.8K ﹤0.01% 937
2018
Q4 		$5K Buy
+697
New +$6.63K ﹤0.01% 1430

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Meeder Asset Management's CBAY Position: Q4 2020 in Review

Meeder Asset Management sold out of Cymabay Therapeutics (CBAY) in Q4 2020, closing a stake of 10,770 shares — an estimated $77K sold.

Meeder Asset Management first reported a position in CBAY in Q4 2018 and held it in 7 quarters. The position peaked at $77K in Q3 2020. 145 funds tracked by Wall St. Rank hold CBAY as of Q4 2020.

  • Meeder Asset Management reported no remaining Cymabay Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Meeder Asset Management sold 10,770 Cymabay Therapeutics shares in Q4 2020, an estimated $77K.
  • Meeder Asset Management first reported a position in Cymabay Therapeutics in Q4 2018 and held it in 7 quarters.
  • Meeder Asset Management's Cymabay Therapeutics position peaked at $77K in Q3 2020.
  • 145 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2020.

Based on Meeder Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.